Beta-Glucan Immunomodulation for STEMI and Digestive Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ST-elevation myocardial infarction (STEMI) and digestive system diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis are inadequate in effectively addressing inflammation and oxidative stress, with a need for more targeted and immunomodulatory therapies.

Innovation Solution

Administration of β-1,3/1,6-D-glucan, derived from Ganoderma lucidum mycellium, which modulates immune response, reduces inflammation, and enhances antioxidant activity through superoxide dismutase and catalase activity, administered in specific dosages and formulations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for STEMI and digestive system diseases, then basic symptom management is achieved, but inflammation and oxidative stress are not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidinflammation and oxidative stress

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter from conventional symptom-management approaches to immunomodulatory therapy using beta-glucan. This polysaccharide specifically targets inflammatory markers and oxidative stress parameters, transforming the treatment approach to address root causes rather than just symptoms.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Beta-glucan acts as an intermediary substance that mediates between the immune system and pathological conditions. It interacts with immune cells to modulate their activity, thereby reducing inflammation and oxidative stress without directly attacking the disease pathology.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If targeted immunomodulatory therapy is implemented, then inflammation and oxidative stress are effectively reduced, but treatment complexity increases

Engineering Contradiction:

Improveinflammatory markersVSAvoidtreatment formulation complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

Beta-glucan exhibits multiple therapeutic functions simultaneously: it modulates immune response, reduces inflammation, and decreases oxidative stress. This multi-functionality allows a single agent to address multiple pathological parameters without requiring complex combination therapies.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs beta-glucan as a composite biological material derived from fungal cell walls. Its complex polysaccharide structure provides multiple active sites for immune cell interaction, enabling simultaneous immunomodulation and anti-inflammatory effects through a single composite substance.

Inventive Principle:

Principle #40Composite materials

3Reliability

If beta-1,3/1,6-D-glucan is administered at therapeutically effective doses, then immune function is enhanced and symptoms are alleviated, but dosage precision requirements increase

Engineering Contradiction:

Improveimmune modulation efficacyVSAvoiddosage accuracy

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent specifies dosage ranges (500-600 mg) rather than fixed doses, allowing dynamic adjustment based on patient response and disease severity. This dynamic dosing approach maintains therapeutic efficacy while accommodating variations in patient metabolism and disease progression.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent employs a therapeutically effective dose range that provides sufficient beta-glucan exposure to achieve immune modulation without requiring excessive precision. The dosage is optimized to ensure minimum effective concentration while allowing reasonable manufacturing tolerances.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

β-1,3/1,6-D-glucan effectively reduces inflammatory markers, improves cardiovascular health, and alleviates symptoms of STEMI and digestive disorders by enhancing immune function and reducing oxidative stress.

Implementation Method 1

β-1,3/1,6-D-glucan, which modulates immune response, reduces inflammation, and enhances antioxidant activity

Methodology Applied

Scientific EffectImmunomodulation:

Implementation Method 2

enhances antioxidant activity through superoxide dismutase and catalase activity

Methodology Applied

Scientific EffectAntioxidant activity:

Data Source

PatentUS20260060997A1Use of Polysaccharide for Treating ST-Elevation Myocardial Infarction and Diseases of the Digestion System

Publication Date: 2026.03.05 PT SAHABAT LINGKUNGAN HIDUP

AI summary

Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using β-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising β-1,3/1,6-D-glucan are also provided.